PUT/EVOTEC/12/0.1/21.06.24 Share Price

Warrant

DE000GP2X9D5

Market Closed - BOERSE MUENCHEN 11:57:13 14/06/2024 pm IST
0.363 EUR +3.71% Intraday chart for PUT/EVOTEC/12/0.1/21.06.24
Current month+1.97%
1 month+89.06%
Date Price Change
14/24/14 0.363 +3.71%
13/24/13 0.35 +13.64%
12/24/12 0.308 -3.45%
11/24/11 0.319 -4.49%
10/24/10 0.334 +4.05%

Real-time BOERSE MUENCHEN

Last update June 14, 2024 at 11:57 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GP2X9D
ISINDE000GP2X9D5
Date issued 13/04/2023
Strike 12
Maturity 21/06/2024 (5 Days)
Parity 10 : 1
Emission price 0.06
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.369
Lowest since issue 0.034
Delta-0.89x
Omega 2.016
Premium1.19x
Gearing2.27x
Moneyness 1.429
Difference Strike 3.6
Difference Strike %+30.00%
Spread 0.02
Spread %5.26%
Theoretical value 0.3700
Implied Volatility 190.72 %
Total Loss Probability 6.946 %
Intrinsic value 0.3600
Present value 0.0100
Break even 8.300 €
Theta-0.01x
Vega0x
Rho-0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.4 EUR
Average target price
20.79 EUR
Spread / Average Target
+147.50%
Consensus